469 related articles for article (PubMed ID: 33762086)
1. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial.
Janda M; Robledo KP; Gebski V; Armes JE; Alizart M; Cummings M; Chen C; Leung Y; Sykes P; McNally O; Oehler MK; Walker G; Garrett A; Tang A; Land R; Nicklin JL; Chetty N; Perrin LC; Hoet G; Sowden K; Eva L; Tristram A; Obermair A
Gynecol Oncol; 2021 Apr; 161(1):143-151. PubMed ID: 33762086
[TBL] [Abstract][Full Text] [Related]
2. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
Zhao X; Niu J; Shi C; Liu Z
Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
[TBL] [Abstract][Full Text] [Related]
3. Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial.
Hawkes AL; Quinn M; Gebski V; Armes J; Brennan D; Janda M; ; Obermair A
Contemp Clin Trials; 2014 Sep; 39(1):14-21. PubMed ID: 24999075
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.
Pal N; Broaddus RR; Urbauer DL; Balakrishnan N; Milbourne A; Schmeler KM; Meyer LA; Soliman PT; Lu KH; Ramirez PT; Ramondetta L; Bodurka DC; Westin SN
Obstet Gynecol; 2018 Jan; 131(1):109-116. PubMed ID: 29215513
[TBL] [Abstract][Full Text] [Related]
5. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
6. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
[TBL] [Abstract][Full Text] [Related]
7. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Dominick S; Hickey M; Chin J; Su HI
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
[TBL] [Abstract][Full Text] [Related]
8. Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: A qualitative study.
O'Hara M; Janda M; McCarthy AL; Nicklin J; Walker G; Obermair A
Gynecol Oncol Rep; 2022 Feb; 39():100914. PubMed ID: 35005158
[TBL] [Abstract][Full Text] [Related]
9. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
[TBL] [Abstract][Full Text] [Related]
10. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
11. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
[TBL] [Abstract][Full Text] [Related]
12. Levonorgestrel-releasing intrauterine device therapy vs oral progestin treatment for reproductive-aged patients with endometrial intraepithelial neoplasia: a systematic review and meta-analysis.
Suzuki Y; Ferris JS; Chen L; Dioun S; Usseglio J; Matsuo K; Xu X; Hershman DL; Wright JD
J Natl Cancer Inst; 2024 May; 116(5):653-664. PubMed ID: 38305500
[TBL] [Abstract][Full Text] [Related]
13. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
[TBL] [Abstract][Full Text] [Related]
14. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby AE; Cooke I; Rees M
Cochrane Database Syst Rev; 2005 Oct; (4):CD002126. PubMed ID: 16235297
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women.
Ravi RD; Kalra J; Srinivasan R; Bagga R; Jain V; Suri V; Sachdeva N
Asian Pac J Cancer Prev; 2021 Mar; 22(3):983-989. PubMed ID: 33773565
[TBL] [Abstract][Full Text] [Related]
16. Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.
Kim MK; Seong SJ; Kang SB; Bae DS; Kim JW; Nam JH; Lim MC; Lee TS; Kim S; Paek J
J Gynecol Oncol; 2019 Mar; 30(2):e47. PubMed ID: 30740964
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer.
Hirata T; Kondo E; Magawa S; Kubo-Kaneda M; Nii M; Yoshida K; Maezawa T; Tabata T; Ikeda T
J Obstet Gynaecol Res; 2022 Dec; 48(12):3219-3225. PubMed ID: 36054237
[TBL] [Abstract][Full Text] [Related]
18. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby A; Hussain M; Rishworth JR; Rees MC
Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
[TBL] [Abstract][Full Text] [Related]
19. Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer.
Hwang JY; Kim DH; Bae HS; Kim ML; Jung YW; Yun BS; Seong SJ; Shin E; Kim MK
Int J Gynecol Cancer; 2017 May; 27(4):738-742. PubMed ID: 28346240
[TBL] [Abstract][Full Text] [Related]
20. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
